174 related articles for article (PubMed ID: 23275306)
21. Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer.
Pothacharoen P; Siriaunkgul S; Ong-Chai S; Supabandhu J; Kumja P; Wanaphirak C; Sugahara K; Hardingham T; Kongtawelert P
J Biochem; 2006 Oct; 140(4):517-24. PubMed ID: 16936295
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
23. Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
Tamada Y; Takeuchi H; Suzuki N; Susumu N; Aoki D; Irimura T
Cancer Sci; 2007 Oct; 98(10):1586-91. PubMed ID: 17711507
[TBL] [Abstract][Full Text] [Related]
24. The expression of CEA, CA 19-9 and HMFG antigens in ovarian clear-cell and endometrioid carcinomas.
Helle M; Helin H; Ashorn P; Putkinen EL; Krohn K; Wahlström T
Pathol Res Pract; 1992 Feb; 188(1-2):74-7. PubMed ID: 1594502
[TBL] [Abstract][Full Text] [Related]
25. Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis.
Higashiguchi A; Yamada T; Susumu N; Mori T; Suzuki A; Aoki D; Sakamoto M
Cancer Sci; 2007 Mar; 98(3):387-91. PubMed ID: 17270029
[TBL] [Abstract][Full Text] [Related]
26. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
[TBL] [Abstract][Full Text] [Related]
27. Endometrioid adenocarcinoma of the ovary mimicking serous borderline tumor: report of a series of cases.
Mansor S; McCluggage WG
Int J Gynecol Pathol; 2014 Sep; 33(5):470-6. PubMed ID: 25083962
[TBL] [Abstract][Full Text] [Related]
28. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
29. The lung-restricted marker napsin A is highly expressed in clear cell carcinomas of the ovary.
Kandalaft PL; Gown AM; Isacson C
Am J Clin Pathol; 2014 Dec; 142(6):830-6. PubMed ID: 25389337
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibody SM047 as an immunohistochemical marker of ovarian adenocarcinoma.
McCluggage WG; Maxwell P; Veenstra H; Fick CE; Laeng RH; Tiltman AJ
Histopathology; 2001 Jun; 38(6):542-9. PubMed ID: 11422498
[TBL] [Abstract][Full Text] [Related]
31. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
32. A novel monoclonal antibody, H9, directed against the core protein of MUC1 mucin.
Hamada H; Kohno N; Yokoyama A; Kondo K; Yang SZ; Hiwada K; Watanabe K; Miyake M
Oncol Rep; 2000; 7(2):225-32. PubMed ID: 10671662
[TBL] [Abstract][Full Text] [Related]
33. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.
Rosen DG; Yang G; Cai KQ; Bast RC; Gershenson DM; Silva EG; Liu J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):632-7. PubMed ID: 15701850
[TBL] [Abstract][Full Text] [Related]
34. Mammaglobin expression in gynecologic adenocarcinomas.
Hagemann IS; Pfeifer JD; Cao D
Hum Pathol; 2013 Apr; 44(4):628-35. PubMed ID: 23084633
[TBL] [Abstract][Full Text] [Related]
35. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
Rubinstein DB; Karmely M; Ziv R; Benhar I; Leitner O; Baron S; Katz BZ; Wreschner DH
Cancer Res; 2006 Dec; 66(23):11247-53. PubMed ID: 17145869
[TBL] [Abstract][Full Text] [Related]
36. Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin.
Dai J; Allard WJ; Davis G; Yeung KK
Tumour Biol; 1998; 19 Suppl 1():100-10. PubMed ID: 9422094
[TBL] [Abstract][Full Text] [Related]
37. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
38. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of highly sulfated chondroitin sulfates in ovarian cancer defined by the single chain antibody GD3A11.
van der Steen SC; van Tilborg AA; Vallen MJ; Bulten J; van Kuppevelt TH; Massuger LF
Gynecol Oncol; 2016 Mar; 140(3):527-36. PubMed ID: 26731725
[TBL] [Abstract][Full Text] [Related]
40. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
